Latest Idiopathic thrombocytopenic purpura Stories
Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura.
The U.S. Food and Drug Administration says it has approved Nplate (romiplostim), the first product that directly stimulates bone marrow platelet production. The FDA said the new drug will be used to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.
Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients.
COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that the U.S.
Amgen has announced new positive data from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura, a chronic and serious autoimmune disorder characterized by low platelet counts in the blood.
PHILADELPHIA, Nov. 28 /PRNewswire-USNewswire/ --
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.